DKSH and BridgeBio Form Alliance to Enhance Patient Access in Asia Pacific Regions.

DKSH's Strategic Partnership with BridgeBio

On June 11, 2026, DKSH announced a pivotal collaboration with BridgeBio to enhance regulatory evaluations and improve patient access to a new Transthyretin Stabilizer specifically for ATTR-CM (Transthyretin Amyloid Cardiomyopathy) in selected Asia Pacific regions, including Australia, Singapore, South Korea, and Taiwan. This partnership symbolizes a significant development in the healthcare sector, promoting innovative treatment solutions for this progressive and debilitating condition.

In the agreement, DKSH is entrusted with the responsibilities of distribution and commercialization of the Transthyretin Stabilizer across the aforementioned countries. The partnership merges BridgeBio's cutting-edge biotechnology research with DKSH Healthcare's comprehensive market expansion capabilities, ensuring that patients gain access to novel treatment options that are currently not available in these markets.

ATTR-CM is known to result from the buildup of amyloid proteins in the heart, leading to severe cardiovascular complications and negatively impacting the quality of life. The new treatment aims to address this by reducing cardiovascular-related death and hospitalizations for those affected. However, any steps towards commercialization will be dependent on the necessary regulatory approvals and adherence to local regulations.

DKSH is poised to leverage its expertise in various areas such as regulatory affairs, medical affairs, and market access to deliver end-to-end solutions that prioritize healthcare access for patients. The company's robust distribution infrastructure and end-to-end commercialization capabilities are vital assets that will support the introduction of this treatment following regulation approvals.

Patrik Grande, Global Head of Business Unit Healthcare at DKSH, emphasized the importance of this strategic alliance: “Our partnership with BridgeBio signifies a key milestone as we embrace a renewed vision for growth. Fueled by a shared commitment to enhance healthcare outcomes for underserved populations, we are well prepared to combine BridgeBio's scientific advancements with our renowned commercialization platform.” He pointed out the necessity of reliable, responsible, and widespread access to new treatments, echoing DKSH's mission to provide healthcare for all.

Founded over 160 years ago, DKSH has established itself as a prominent Market Expansion Services provider, equipped to deliver a spectrum of services including sourcing, market insights, e-commerce, and logistics across various sectors, including healthcare, consumer goods, technology, and performance materials. With its participation in the United Nations Global Compact, DKSH embodies a responsible business framework that prioritizes social responsibility.

In 2025, DKSH recorded considerable growth with net sales exceeding CHF 11.1 billion, and its healthcare division alone generated net sales of CHF 5.8 billion. As the healthcare landscape continues to evolve with the emergence of genetic diseases and innovative therapies, partnerships like the one between DKSH and BridgeBio are crucial in transforming patient access to effective treatments.

This strategic collaboration heralds a significant leap toward addressing the unmet clinical needs of patients suffering from ATTR-CM, offering new hope through improved treatment access and pioneering health solutions in the Asia Pacific region.